Critical review of nonsurgical treatment options for stage I non-small cell lung cancer

Oncologist

Volumn 13, Issue 3, 2008, Pages 309-319

  Haasbeek, Cornelis J A ^a   Senan, Suresh ^a   Smit, Egbert F ^a   Paul, Marinus A ^a   Slotman, Ben J ^a   Lagerwaard, Frank J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Lung cancer; Radiofrequency ablation; Radiotherapy; Stage I; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN;

BLEEDING; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; GERIATRIC PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MORBIDITY; NON INVASIVE PROCEDURE; PNEUMOTHORAX; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIOFREQUENCY ABLATION; REVIEW; STEREOTACTIC PROCEDURE; STEREOTACTIC RADIATION THERAPY; TOXICITY; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; STEREOTAXIC TECHNIQUES;

EID: 43549121965     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0195     Document Type: Review

References (102)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. Little AG, Gay EG, Gaspar LE et al. National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of care. Lung Cancer 2007;57:253-260.
3. Martini N, Bains MS, Burt ME et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-129.
4. Goya T, Asamura H, Yoshimura H et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study. Lung Cancer 2005;50:227-234.
5. Duque JK, Lopez-Encuentra A, Rami-Porta R; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery. Survival of 2,991 patients with surgical lung cancer: The denominator effect in survival. Chest 2005;128:2274-2281.
6. Rami-Porta R, Ball D, Crowley J et al.; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602.
7. Manser R, Wright G, Hart D et al. Surgery for early stage non-small cell lung cancer. Cochrane Database Syst Rev 2005;(1):CD004699.
8. Janssen-Heijnen ML, Schipper RM, Razenberg PP et al. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: A population-based study. Lung Cancer 1998;21:105-113.
9. Mery CM, Pappas AN, Bueno R et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the Surveillance, Epidemiology, and End Results database. Chest 2005;128:237-245.
10. Wisnivesky JP, Bonomi M, Henschke C et al. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest 2005;128:1461-1467.
11. Raz DJ, Zell JA, Ou SH et al. Natural history of stage I non-small cell lung cancer: Implications for early detection. Chest 2007;132:193-199.
12. Bach PB, Cramer LD, Schrag D et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181-188.
13. Allen MS, Darling GE, Pechet TT et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: Initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006;81:1013-1019; discussion 1019-1020.
14. Wada H, Nakamura T, Nakamoto K et al. Thirty-day operative mortality for thoracotomy in lung cancer. J Thorac Cardiovasc Surg 1998;115:70-73.
15. Gauger J, Patz EF Jr, Coleman RE et al. Clinical stage I non-small cell lung cancer including FDG-PET imaging: Sites and time to recurrence. J Thorac Oncol 2007;2:499-505.
16. Martin-Ucar AE, Nakas A, Pilling JE et al. A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-risk patients. Eur J Cardiothorac Surg 2005;27:675-679.
17. Pasini F, Verlato G, Durante E et al. Persistent excess mortality from lung cancer in patients with stage I non-small-cell lung cancer, disease-free after 5 years. Br J Cancer 2003;88:1666-1668.
18. Lopez-Encuentra A, Gomez de la Camara A, Rami-Porta R et al. Previous tumour as a prognostic factor in stage I non-small cell lung cancer. Thorax 2007;62:386-390.
19. Birim O, Kappetein AP, Goorden T et al. Proper treatment selection may improve survival in patients with clinical early-stage nonsmall cell lung cancer. Ann Thorac Surg 2005;80:1021-1026.
20. Daniels JM, Eerenberg JP, Rijna H et al. Mitotic index does not predict prognosis in stage IA non-small cell lung cancer. Lung Cancer 2002;38:163-167.
21. Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy: Optimal management strategy using decision analysis techniques. Ann Thorac Surg 2003;76:1782-1788.
22. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60:615-622; discussion 622-623.
23. Kodama K, Doi O, Higashiyama M et al. Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: A single-institution study. J Thorac Cardiovasc Surg 1997;114:347-353.
24. El-Sherif A, Gooding WE, Santos R et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: A 13-year analysis. Ann Thorac Surg 2006;82:408-415; discussion 415-416.
25. Warren WH, Faber LP. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. Five-year survival and patterns of intrathoracic recurrence. J Thorac Cardiovasc Surg 1994;107:1087-1093; discussion 1093-1094.
26. Lederle FA. Lobectomy versus limited resection in T1 N0 lung cancer. Ann Thorac Surg 1996;62:1249-1250.
27. Nakamura H, Kawasaki N, Taguchi M et al. Survival following lobectomy vs limited resection for stage I lung cancer: A meta-analysis. Br J Cancer 2005;92:1033-1037.
28. McKenna RJ Jr, Houck WV. New approaches to the minimally invasive treatment of lung cancer. Curr Opin Pulm Med 2005;11:282-286.
29. Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer. World J Surg 2000;24:27-30; discussion 30-31.
30. Kirby TJ, Mack MJ, Landreneau RJ et al. Lobectomy-video-assisted thoracic surgery versus muscle-sparing thoracotomy. A randomized trial. J Thorac Cardiovasc Surg 1995;109:997-1001; discussion 1001-1002.
31. Atkins BZ, Harpole DH, Jr., Mangum JH et al. Pulmonary segmentectomy by thoracotomy or thoracoscopy: Reduced hospital length of stay with a minimally-invasive approach. Ann Thorac Surg 2007;84:1107-1112; discussion 1112-1113.
32. Swanson SJ, Batirel HF. Video-assisted thoracic surgery (VATS) resection for lung cancer. Surg Clin North Am 2002;82:541-559.
33. Ali MK, Ewer MS, Atallah MR et al. Regional and overall pulmonary function changes in lung cancer. Correlations with tumor stage, extent of pulmonary resection, and patient survival. J Thorac Cardiovasc Surg 1983;86:1-8.
34. Nakahara K, Monden Y, Ohno K et al. A method for predicting postoperative lung function and its relation to postoperative complications in patients with lung cancer. Ann Thorac Surg 1985;39:260-265.
35. Win T, Groves AM, Ritchie AJ et al. The effect of lung resection on pulmonary function and exercise capacity in lung cancer patients. Respir Care 2007;52:720-726.
36. Sarna L, Evangelista L, Tashkin D et al. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of nonsmall cell lung cancer. Chest 2004;125:439-445.
37. Handy JR Jr, Asaph JW, Skokan L et al. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest 2002;122:21-30.
38. Karmakar MK, Ho AM. Postthoracotomy pain syndrome. Thorac Surg Clin 2004;14:345-352.
39. Rogers ML, Duffy JP. Surgical aspects of chronic post-thoracotomy pain. Eur J Cardiothorac Surg 2000;18:711-716.
40. Little AG, Rusch VW, Bonner JA et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005;80:2051-2056.
41. Jaklitsch MT, Mery CM, Audisio RA. The use of surgery to treat lung cancer in elderly patients. Lancet Oncol 2003;4:463-471.
42. Damhuis R, Coonar A, Plaisier P et al. A case-mix model for monitoring of postoperative mortality after surgery for lung cancer. Lung Cancer 2006;51:123-129.
43. Qiao X, Tullgren O, Lax I et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003;41:1-11.
44. Mehta M, Scrimger R, Mackie R et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;49:23-33.
45. Kavanagh BD, McGarry RC, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 2006;16:77-84.
46. Fowler JF, Tome WA, Fenwick JD et al. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004;60:1241-1256.
47. McGarry RC, Papiez L, Williams M et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study. Int J Radiat Oncol Biol Phys 2005;63:1010-1015.
48. Nagata Y, Takayama K, Matsuo Y et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-1431.
49. Onishi H, Araki T, Shirato H et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623-1631.
50. Baumann P, Nyman J, Lax I et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006;45:787-795.
51. Lagerwaard FJ, Haasbeek CJ, Slotman BJ et al. Clinical results and toxicity after 4-dimensional stereotactic radiotherapy for early stage nonsmall cell lung cancer (NSCLC): B5-04. J Thorac Oncol 2007;2(suppl 4):S348.
52. Onishi H, Shirato H, Nagata Y et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2(suppl 3):S94-S100.
53. Strand TE, Rostad H, Moller B et al. Survival after resection for primary lung cancer: A population based study of 3211 resected patients. Thorax 2006;61:710-715.
54. Bradley J. Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2007;2(suppl 3):S118-S124.
55. Timmerman R, McGarry R, Yiannoutsos C et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-4839.
56. Wulf J, Baier K, Mueller G et al. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005;77:83-87.
57. Lagerwaard FJ, van der Geld Y, Slotman BJ et al. 1009: Quality of life after stereotactic radiotherapy for medically inoperable stage I lung cancer. Int J Radiat Oncol Biol Phys 2006;66(suppl 1):S133-S134.
58. Ohashi T, Takeda A, Shigematsu N et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys 2005;62:1003-1008.
59. Henderson MA, McGarry RC, Yiannoutsos C et al. 162: Stereotactic body radiotherapy for early stage non-small-cell lung cancer in patients with very poor pulmonary function. Int J Radiat Oncol Biol Phys 2006;66(suppl 1):S91.
60. Higgins H, Berger DL. RFA for liver tumors: Does it really work? The Oncologist 2006;11:801-808.
61. Lencioni R, Crocetti L, Cioni R et al. Radiofrequency ablation of lung malignancies: Where do we stand? Cardiovasc Intervent Radiol 2004;27:581-590.
62. Iguchi T, Hiraki T, Gobara H et al. Percutaneous radiofrequency ablation of lung tumors close to the heart or aorta: Evaluation of safety and effectiveness. J Vasc Interv Radiol 2007;18:733-740.
63. Abbas G, Schuchert MJ, Pennathur A et al. Ablative treatments for lung tumors: Radiofrequency ablation, stereotactic radiosurgery, and microwave ablation. Thorac Surg Clin 2007;17:261-271.
64. Simon CJ, Dupuy DE, Dipetrillo TA et al. Pulmonary radiofrequency ablation: Long-term safety and efficacy in 153 patients. Radiology 2007;243:268-275.
65. de Baere T, Palussiere J, Auperin A et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: Prospective evaluation. Radiology 2006;240:587-596.
66. Hiraki T, Tajiri N, Mimura H et al. Pneumothorax, pleural effusion, and chest tube placement after radiofrequency ablation of lung tumors: Incidence and risk factors. Radiology 2006;241:275-283.
67. Yan TD, King J, Sjarif A et al. Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol 2007;14:1718-1726.
68. FDA Public Health Notification: Deaths Reported Following Radio Frequency Ablation of Lung Tumors. Publication Date: December 11, 2007. Available at http://www.fda.gov/cdrh/safety/121107-rfablation.html. Accessed December 21, 2007.
69. van Iersel CA, de Koning HJ, Draisma G et al. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007;120:868-874.
70. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-1608.
71. Sawada S, Yamashita M, Komori E et al. Evaluation of resected tumors that were not diagnosed histologically but were suspected of lung cancer preoperatively: PD1-3-5. J Thorac Oncol 2007;2(suppl 4):S422.
72. Swensen SJ, Silverstein MD, Ilstrup DM et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 1997;157:849-855.
73. Herder GJ, van Tinteren H, Golding RP et al. Clinical prediction model to characterize pulmonary nodules: Validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest 2005;128:2490-2496.
74. van Tinteren H, Hoekstra OS, Smit EF et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial. Lancet 2002;359:1388-1393.
75. Spira A, Beane JE, Shah V et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007;13:361-366.
76. Kikuchi T, Carbone DP. Proteomics analysis in lung cancer: Challenges and opportunities. Respirology 2007;12:22-28.
77. McWilliams A, Mayo J, MacDonald S et al. Lung cancer screening: A different paradigm. Am J Respir Crit Care Med 2003;168:1167-1173.
78. Zeng H, McWilliams A, Lam S. Optical spectroscopy and imaging for early lung cancer detection: A review. Photodiagn Photodyn Ther 2004;1:111-122.
79. Vergnon JM, Huber RM, Moghissi K. Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Respir J 2006;28:200-218.
80. Taulelle M, Chauvet B, Vincent P et al. High dose rate endobronchial brachytherapy: Results and complications in 189 patients. Eur Respir J 1998;11:162-168.
81. McCaughan JS Jr, Williams TE. Photodynamic therapy for endobronchial malignant disease: A prospective fourteen-year study. J Thorac Cardiovasc Surg 1997;114:940-946.
82. Pignon JP, Tribodet H, Scagliotti GV et al. Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2006;24(18 suppl):366S.
83. Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
84. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580.
85. Ohtsuka T, Nomori H, Watanabe K et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006;107:2468-2473.
86. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
87. Rusch VW, Crowley J, Giroux DJ et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:603-612.
88. Postmus PE, Brambilla E, Chansky K et al. The IASLC Lung Cancer Staging Project: Proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686-693.
89. Thomas P, Doddoli C, Thirion X et al. Stage I non-small cell lung cancer: A pragmatic approach to prognosis after complete resection. Ann Thorac Surg 2002;73:1065-1070.
90. Ludwig C, Stoelben E, Olschewski M et al. Comparison of morbidity, 30-day mortality, and long-term survival after pneumonectomy and sleeve lobectomy for non-small cell lung carcinoma. Ann Thorac Surg 2005;79:968-973.
91. Harpole DH Jr, DeCamp MM Jr, Daley J et al. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. J Thorac Cardiovasc Surg 1999;117:969-979.
92. Reilly JJ, Jr. Evidence-based preoperative evaluation of candidates for thoracotomy. Chest 1999;116(6 suppl):474S-476S.
93. Benzo R, Kelley GA, Recchi L et al. Complications of lung resection and exercise capacity: A meta-analysis. Respir Med 2007;101:1790-1797.
94. Burke JR, Duarte IG, Thourani VH et al. Preoperative risk assessment for marginal patients requiring pulmonary resection. Ann Thorac Surg 2003;76:1767-1773.
95. Iizasa T, Suzuki M, Yasufuku K et al. Preoperative pulmonary function as a prognostic factor for stage I non-small cell lung carcinoma. Ann Thorac Surg 2004;77:1896-1902; discussion 1902-1903.
96. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer - mature results for medically inoperable patients. Lung Cancer 2006;51:97-103.
97. Uematsu M, Shioda A, Suda A et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670.
98. Xia T, Li H, Sun Q et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;66:117-125.
99. Sakurai J, Hiraki T, Mukai T et al. Intractable pneumothorax due to bronchopleural fistula after radiofrequency ablation of lung tumors. J Vasc Interv Radiol 2007;18:141-145.
100. Hiraki T, Sakurai J, Tsuda T et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors: Evaluation based on a preliminary review of 342 tumors. Cancer 2006;107:2873-2880.
101. Yamagami T, Kato T, Hirota T et al. Pneumothorax as a complication of percutaneous radiofrequency ablation for lung neoplasms. J Vasc Interv Radiol 2006;17:1625-1629.
102. Kang S, Luo R, Liao W et al. Single group study to evaluate the feasibility and complications of radiofrequency ablation and usefulness of post treatment positron emission tomography in lung tumours. World J Surg Oncol 2004;2:30.